Novavax, Inc. (NASDAQ:NVAX) is one of the top long-term biotechnology stocks to buy. On October 24, Cantor Fitzgerald ...

The consensus analyst price target for Novavax stock has edged up from $12.50 to $13.21, reflecting an evolving outlook as the company navigates a transition in its business strategy. This shift ...

Find out how different vaccines for the coronavirus cause your body to create antibodies that fight the virus.

The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older. The Novavax vaccine is protein ...

According to the authors, vaccine effectiveness against infection reached 44.7% (95% confidence interval [CI], 37.7% to 50.9% ...

Many states have already announced their own Covid vaccine recommendations, creating "unprecedented" levels of confusion, one ...

Flu season is here. The summer wave of the coronavirus has receded, but the winter uptick is likely around the corner. Shots ...

The French pharma’s overall vaccine sales declined 8% in the quarter, with a key driver being slower-than-usual uptake of flu ...

A troubled Indiana contract manufacturing plant recently acquired by Novo Nordisk is considered to not be in compliance with FDA standards ...

NEW YORK (AP) — A more traditional kind of COVID-19 vaccine has moved a step closer to the U.S. market. Advisers to the Food and Drug Administration voted Tuesday to back shots made by Novavax for U.S ...

(Reuters) - Novavax Inc has begun a large late-stage study of its experimental COVID-19 vaccine in the United States, the drug developer said on Monday, after delaying the trial twice due to issues in ...

Oct 27 (Reuters) - Novavax Inc (NVAX.O), opens new tab on Tuesday delayed the start of a late-stage U.S. trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing ...